Topic:

M&A

Latest Headlines

Latest Headlines

Zimmer to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close

Zimmer already has clearances from regulators in Europe and Japan for its proposed $13.4 billion acquisition of Biomet. Now it's close to gaining the go-ahead from the U.S. Federal Trade Commission. Zimmer has disclosed that it has secured buyers for three U.S. businesses to satisfy FTC requests: Zimmer Unicompartmental High-Flex Knee System assets, Biomet Discovery Elbow System assets and Cobalt bone cement assets.

Betting on Pfizer merger--or CEO goodbye--traders go bullish on Glaxo

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.

Bayer chief may plow spinoff cash into animal health buys

Bayer has seen many an M&A opportunity come and go when it comes to bolstering its animal health unit. But once it jettisons its plastics unit--a move that could generate some extra dough--it might finally be ready to strike a deal.

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.

France's Labco sells to Cinven for $1.3B after pumping brakes on IPO

French medical diagnostics outfit Labco is selling out to U.K. private equity firm Cinven for €1.2 billion ($1.3 billion), shifting gears after abandoning its previously announced IPO.

Ergomed snags a postmarketing firm with its eye on pharmacovigilance

U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.

Happy anniversary? Taking stock at Pfizer, AstraZeneca one year after the mega-mega-deal collapse

One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.

Sanofi splurges $245M on Retrophin's speedy-review voucher

Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.

Hold the offer: Bavarian Nordic declares it's not for sale

Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.

Valeant chief Pearson won't be scared off by M&A 'bubble'

Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."